Periodic Reporting for period 1 - MABank (Creation of a GLP bank of immune-privileged, immortal mesoangioblasts to treat monogenic, recessive diseases of muscle and connective tissue)

Stem cells led to effective cures for diseases of blood and epithelia but now face the problem of the extremely high costs of production (up to 2M$ for a single produt). This will make such therapies unsustainable for NHS. Through the ongoing ERC ADG 884952-UniMab, we are...